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Miyabeacin: A new cyclodimer 
presents a potential role for willow 
in cancer therapy
Jane L. Ward  1*, Yanqi Wu1,2, claudia Harflett1, Hannah onafuye3, Delia corol1, 
charlotte Lomax1, William J. Macalpine  1, Jindrich cinatl Jr.  4, Mark n. Wass  3, 
Martin Michaelis  3 & Michael H. Beale1*
Willow (Salix spp.) is well known as a source of medicinal compounds, the most famous being salicin, 
the progenitor of aspirin. Here we describe the isolation, structure determination, and anti-cancer 
activity of a cyclodimeric salicinoid (miyabeacin) from S. miyabeana and S. dasyclados. We also show 
that the capability to produce such dimers is a heritable trait and how variation in structures of natural 
miyabeacin analogues is derived via cross-over Diels-Alder reactions from pools of ortho-quinol 
precursors. these transient ortho-quinols have a role in the, as yet uncharacterised, biosynthetic 
pathways around salicortin, the major salicinoid of many willow genotypes.
The utility of willow bark in medicine was recorded by ancient Greek, Assyrian and Egyptian civilisations, but the 
first scientifically reported investigation of willow (Salix spp.) as a remedy for fever was in 17631. The isolation of 
an active principle, salicin 1 (Fig. 1)2,3, was followed by a period of prescription of willow components for pain 
relief until 1897 when the Bayer Company produced the synthetic analogue, aspirin (acetylsalicylate), one of the 
earliest and most successful nature-inspired drugs. The medicinal mode of action of aspirin is via irreversible 
acylation of cyclooxygenase isoforms (COX-1 and COX-2) which are key enzymes in prostaglandin biosynthesis4. 
However, both salicin and aspirin are metabolised in humans to salicylic acid, which also inhibits COX via a com-
petitive mechanism5, which, in part, explains the efficacy of willow bark extracts. However, recent work indicates 
that salicin itself may have anti-inflammatory properties via interaction with other components of the cytokine 
signalling complex6. Besides the established uses of aspirin for pain relief and also its prescription for the miti-
gation of thrombosis, via the involvement of COX-1 in thromboxane A2 mediated platelet aggregation7, there is 
now a renewed interest in the possibility of additional pharmacologies of salicinoids, for example in cancer ther-
apy8–11. It has also been suggested that the medicinal activity of herbal extracts of willow cannot be accounted for 
by the levels of salicin alone12,13, indicating a potential for new bio-active or synergistic metabolites. Furthermore, 
there is now increased clinical interest in utilising willow bark extractives, particularly in the long-term treatment 
of arthritic pain14,15.
The natural salicinoids comprise a sub-group of the wider family of phenolic glycosides that is abundant in 
the Salicaceae. The known salicinoid structures appear to be derived from variations in acyl group identity and 
substitution pattern amongst glucose and salicyl hydroxy groups of the salicin base structure16. Salicortin 2, which 
contains an unusual 1-hydroxy-6-oxocyclohex-2-ene-1-carboxylic ester (HCC) function, usually co-occurs with 
salicin 1 and together they are found in many species. Surprisingly, the biosynthetic route to these compounds 
remains largely unknown17. Possibly because of the success of aspirin, medicinal assessment of other salicinoids in 
willow has been mostly neglected by modern science. The potential to discover novel medicinal entities, together 
with an opportunity to shed light on the biosynthetic pathway, via the identification of candidate intermediates, 
led us to take an integrated metabolomics approach to define the diversity and dynamics of salicinoid production 
in willow. In this endeavour, we have been screening members of the UK National Willow Collection, a living 
resource containing over 1500 diverse Salix lines, collected from all over the world. We have recently reported18 
on salicin-7-sulfate, an analogue that requires further pharmacological investigation as it occurs in those species 
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used in commercial herbal products. In this paper we report on new, structurally intriguing, dimeric salicinoids 
that have activity against a panel of cancer cell lines. We also demonstrate that the intermolecular Diels-Alder 
process that leads to this family of molecules is a genetically heritable trait and that the obligate monomeric tran-
sient precursor could be a key molecule in the elusive salicortin biosynthetic pathway.
Results
Identification, structural determination and bioactivity of miyabeacin 3. The LC-MS profiles of 
aqueous methanol extracts of young rapidly growing, stem and leaf tissue of Salix miyabeana Seemen “Shrubby”, 
harvested at growth stage 30–32, according to the published phenological scale19 are shown in Fig. 2. The nega-
tive ion LC-MS total ion chromatogram of stem tissue was dominated by the known compounds salicin, 1 and 
salicortin 2 which were also present in leaf samples alongside known flavonoid glycosides. An additional large 
peak with an [M-H]− ion at m/z 843.2353 appeared at 25.26 min. This peak was present in both leaf and stem 
tissues (Fig. 2) from the same harvest. The accurate mass data (Supplementary Fig. 1) suggested a formula of 
C40H43O20 for the ion (calculated m/z 843.2348) and thus a molecular formula of C40H44O20 for the novel com-
pound 3. A smaller ion corresponding to the formate adduct (m/z 889.2396, C41H45O22.) was also observed. Other 
small ions present in the mass spectrum appeared at m/z 557.1300 (C27H25O13), 421.1140 (C20H21O10), 331.1034 
(C14H19O9) and 217.0507 (C12H9O4). MS-MS of the precursor ion m/z 843.2353 ion did not produce a daughter 
m/z 421 ion indicating that m/z 843.2353 was not a [2M-H]− ion formed in the MS-source from a smaller mol-
ecule with molecular weight 422. Instead the MS-MS revealed a variety of low abundance fragments including 
m/z 123.0438 (C7H7O2), 183.0463 (C12H7O2), 201.0568 (C12H9O3), 219.0687 (C12H11O4), 227.0364 (C13H7O4), 
245.0471 (C13H9O5), 263.0582 (C13H11O6), 289.0362 (C14H9O7) and 557.1374 (C27H25O13) (Supplementary Fig. 2). 
MS-MS of the small m/z 421.1140 ion in the original spectrum provided more insight into the potential structure 
with clear fragments at m/z 297.0626 (C13H13O8), 153.0201 (C7H5O4), 135.0094 (C7H3O3), 123.0447 (C7H7O2), 
109.0277 (C6H5O2) and 81.0368 (C5H5O). This pattern of ions was very similar to that observed from MS-MS of 
the precursor ion (m/z 423) of salicortin 2 (C20H24O10) except for differences of 2 mass units in ions retaining the 
cyclohexenyl ring substructure (m/z 297 vs 299; 153 vs 155; 81 vs 83) (Supplementary Fig. 3). Ions arising from 
the salicyl portion of the salicortin molecule (m/z 123.0447) were retained in 2 and 3. These MS data together 
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Figure 1. Structures. Carbon numbering system and stereochemical depiction for salicin and salicortin follows 
that of Feistel et al.2. For clarity, and to reflect biosynthetic provenance, the salicinoid numbering has been 
maintained in the numbering of miyabeacin and derivatives.
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suggested that the novel molecule (MW 844) may contain at least one dehydro-salicortin moiety where the HCC 
ring now possessed an additional double bond.
For full structure determination by NMR, 3 was isolated via a larger scale extraction of S. miyabeana tissue 
and collection of the appropriate peak from semi-preparative HPLC. The 1H NMR spectrum of 3 showed peaks 
relating to 34 coupled hydrogens (Table 1 and Supplementary Fig. 4). Four signals were observed between δ7.34–
7.10 and matched those observed for the salicyl ring hydrogens in salicortin (Supplementary Fig. 4). However, 
in 3 the integration of the aromatic peaks corresponded to 8 hydrogens suggestive of two such salicyl rings. 
This was confirmed by the presence of two pairs of J = 12 Hz doublet signals relating to the distinctive salicyl 
hydroxymethylene group (pair 1: δ5.40 and δ5.19; pair 2: δ5.38 and δ5.16). Similarly, the molecule appeared 
to contain two separate β-glucoside moieties since characteristic doublet signals relating to the H-1′ anomeric 
hydrogen atoms were duplicated (δ5.09 and δ5.07) as were those corresponding to the glucosyl 6′-methylenes. 
Unlike the 1H-NMR spectrum of salicortin 2 which showed aliphatic signals corresponding to the four meth-
ylene hydrogens of the HCC ring between δ2.94 and 2.51, the spectrum of 3 showed no signals in this region 
indicating a significant change in this part of the molecule. Similarly, signals from the olefinic hydrogens in the 
HCC-ring that appear in the salicortin 1H-NMR spectrum at δ6.27 and δ5.76 each as a doublet of triplets, were 
absent. In 3 these signals were replaced by four separate olefin signals between δ6.60 and 5.85 each integrating for 
one hydrogen, two appearing as double doublets and the others as simple triplets. A dienone arrangement was 
ruled out after examination of the 1H-1H COSY spectrum (Supplementary Fig. 5) which clearly demonstrated 
that although two double bonds were present in the molecule, they were isolated from each other. Integration 
of the carbohydrate region (δ3.96–3.40) in the 1D spectrum suggested a total of sixteen coupled hydrogens. Of 
these, twelve could be accounted for in two glucose units leaving four unaccounted for. 13C NMR data (Table 2 
and Supplementary Fig. 6) confirmed the presence of forty carbon atoms in the molecule including two ketone 
carbonyls at δ198.6 and δ210.0 and two ester carbonyls at δ173.6 and δ173.2 whilst 13C DEPT identified four 
non-aromatic methine signals, in addition to those of glucose (x2) and the two olefins indicated in the 1H spec-
trum (Supplementary Fig. 7). Given the molecular formula from accurate mass, the similarity in fragmentation 
pattern of the smaller m/z 421 fragment to that of salicortin, and the duplication of benzyl and glycosyl related 
NMR signals we postulated 3 was an unsymmetrical dimeric structure formed via condensation of two molecules 
of a salicortin analogue with dehydro-HCC rings. To satisfy the observed spectral data we concluded that the 
dimeric molecule had arisen via a [4 + 2] Diels–Alder cyclodimerisation reaction, between two “salicortenone”, 4 
(Fig. 1) monomer units, one acting as the diene, and the second as the dienophile. The deduced structure of 3 has 
a diketo-1,4-ethenodecalin core, bearing pendant carboxy groups esterified with two salicin units and is shown 
in Fig. 1 and was named miyabeacin 3.
Re-analysis of the smaller fragment ions in the mass spectrum of miyabeacin (Supplementary Fig. 1), showed 
that m/z 331.1034 corresponded to the formate adduct of salicin, 1, m/z 421.1140 to the retro-Diels-Alder product 
“salicortenone” 4, m/z 557.1300 to a mono-desalicylated dimeric moiety and the fragment ion m/z 217.0507, cor-
responding to the cyclo-dimer core structure (C12H9O4) resulting from the loss of both carboxyl side chains. Final 
confirmation of the structure came from analysis of HSQC and HMBC NMR data (Supplementary Figs. 8 and 9). 
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Figure 2. LC-MS data of NWC885 S. miyabeana in negative ion mode. (A) Total ion chromatogram of juvenile 
stem tissue; (B) Total ion chromatogram of juvenile leaf tissue. Numbered peaks are labelled according to the 
compound numbering in Fig. 1. Additional peaks labelled a-f are identified as follows: a: luteolin-7-glucoside; b: 
unknown; c: kaempferol acetyl glucoside isomer; d: kaempferol acetyl glucoside isomer; e: unknown; f: luteolin.
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Key correlations in the 1H-13C HMBC were observed around all of the positions of the dimeric core structure 
(Supplementary Table 1) and between H-10 (δ3.60) and C-8 (δ173.6) confirming the attachment of a carboxyl 
group to the core structure at C-9. The correlation between H-7 (δ5.19 and 5.40) and C-8 (δ173.6) confirmed the 
linkage via the ester carbonyl, to a salicyl moiety. Similar correlations were observed between H-15 (δ3.50) to 
C-21 (δ173.2) and also between H-22 (δ5.16 and δ5.38) and C-21 (δ173.2), suggesting a second carboxy-salicyl 
entity attached to the 1,4-ethenodecalin core at C-20. Additional correlations between C-1 (δ158.0) and H-7 
(δ5.19 and δ5.40) and H-1′ (δ5.09 / 5.07) and also between C-28 (δ157.7) to H-22 (δ5.16 and δ5.38) and H-1′′ 
(δ5.07 /5.09) were consistent with placement of the O-glucosides at C-1 and C-28.
Position 2 3 6 7
1 — — —
2 7.22 (d, 8.1) 7.19 (d, 8.3) 7.20 (d, 8.2) 7.19 (d, 8.0)
3 7.43 (ddd, 8.0, 7.5, 1.9) 7.41 (ddd, 8.0, 7.5, 2.0) 7.43 (ddd, 8.5, 7.5, 1.5) 7.40 (m)
4 7.14 (dt, 7.3, 0.9) 7.12 (t, 7.5)/ 7.11 (t, 7.5) 7.12 (ddd, 7.5, 7.4, 0.9) 7.12 (td, 7.5, 0.9)
5 7.38 (dd, 7.5, 1.6) 7.32 (dd, 7.6, 1.5) / 7.34 (dd, 7.6.1.5) 7.35 (dd, 7.5, 1.5) 7.31 (dd, 7.6, 1.5)
6 — — — —
7α 5.42 (d, 12.2) 5.40 (d, 11.9) 5.46 (d, 11.7) 5.39 (d, 11.9)
7β 5.27 (d, 12.2) 5.19 (d, 11.9) 5.13 (d, 11.7) 5.18 (d, 11.9)
8 — — — —
9 — — — —
10 5.76 (dt, 9.8, 1.6) 3.59–3.63 (m) 2.76 (dd, 4.4, 2.1) 3.57–3.61 (m)
11 6.27 (dt, 10.0, 3.7) 3.58–3.55 (m) 2.99 (m) 3.48–3.53 (m)
12 2.62–2.69 (m) & 2.51–2.57 (m) 6.59 (dd, 10.2, 4.1) 2.88 (m) 6.63 (dd, 10.2, 4.1)
13 2.88–2.94 (m) & 2.57–2.62 (m) 6.02 (dd, 10.2, 1.5) 3.12 (dd, 7.6, 4.0) 6.02 (dd, 10.1, 1.7)
14 — — — —
15 — 3.50–3.53 (m) 2.76 (dd, 4.4, 2.1) 3.28–3.33 (m)
16 — 6.19 (t, 7.9) 2.99 (m) 6.27 (ddd, 7.9, 6.9, 1.0)
17 — 5.91 (ddd, 7.9, 6.5, 1.4) 2.88 (m) 5.94 (1 H, ddd, 7.9, 6.5, 1.4)
18 — 3.43 (m) 3.12 (dd, 7.6, 4.0) 3.36 (1 H, ddd, 6.0, 2.4, 1.4)
19 — — — —
20 — — — —
21 — — — —
22β — 5.38 (d, 12.1) 5.46 (d, 11.7) —
22α — 5.16 (d, 12.1) 5.13 (d, 11.7)
23 — —
24 — 7.32 (dd, 7.6, 1.5)/ 7.34 (dd, 7.6.1.5) 7.35 (dd, 7.5, 1.5)
25 — 7.12 (t, 7.5)/7.11 (t, 7.5) 7.12 (ddd, 7.5, 7.4, 0.9)
26 — 7.41 (ddd, 8.0, 7.5, 2.0) 7.43 (ddd, 8.5, 7.5, 1.5)
27 — 7.20 (d, 8.3) 7.20 (d, 8.2)
28 — —
1′ 5.10 (d, 7.6) 5.09 (d, 7.5)/5.07 (d, 7.8) 5.07 (d, 7.8) 5.06 (d, 7.3)
2′ 3.56 (m) 3.55–3.63 (m) 3.51 (dd, 9.4, 7.8) 3.49–3.59 (m)
3′ 3.57–3.62 (m) 3.56–3.62 (m) 3.58 (m) 3.54–3.61 (m)
4′ 3.45–3.50 (m) 3.47–3.52 (m) 3.45 (t, 9.4) 3.45–3.53 (m)
5′ 3.57–3.62 (m) 3.56–3.62 (m) 3.58 (m) 3.54–3.61 (m)
6′β 3.74 (dd, 12.6, 5.9) 3.77 (dd, 12.4, 6.0)/3.73 (dd, 12.4, 6.0) 3.72 (dd, 12.4, 6.0) 3.76 (dd, 12.5, 5.9)
6′α 3.92 (dd, 12.6, 2.4) 3.94 (dd, 12.4, 2.1)/3.92 (dd, 12.4, 2.1) 3.99 (dd, 12.5, 2.2) 3.92 (dd, 12.4, 2.2)
1″ — 5.09 (d, 7.5)/5.07 (d, 7.8) 5.07 (d, 7.8)
2″ — 3.55–3.63 (m) 3.51 (dd, 9.4, 7.8)
3″ — 3.56–3.62 (m) 3.58 (m)
4″ — 3.47–3.52 (m) 3.45 (t, 9.4)
5″ — 3.56–3.62 (m) 3.58 (m)
6″β — 3.77 (dd, 12.4, 6.0)/3.73 (dd, 12.4, 6.0) 3.72 (dd, 12.4, 6.0)
6″α — 3.94 (dd, 12.4, 2.1)/3.92 (dd, 12.4, 2.1) 3.99 (dd, 12.5, 2.2)
Table 1. 1H-NMR data (600 MHz, D2O:CD3OD (80:20) referenced to d4-TSP (0.01%) at δ0.00) for compounds 
2, 3, 6 and 7. δin ppm; J in Hz.
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The structure represents a completely new and unusual salicinoid. However, the aglycone has structural simi-
larity to grandifloracin 5 (Fig. 1), a natural product first isolated from Uvaria grandiflora [(−) enantiomer]20 and 
later from Uvaria dac [(+) enantiomer] by Awale et al., who demonstrated that the molecule had potent activity 
against human pancreatic cancer cells21. The structure of (+)-grandifloracin has been confirmed by both synthe-
sis22,23 and by X-ray crystallography21. Inspection of the published NMR data21,23 relating to the olefin and bridge-
head methine hydrogens from grandifloracin agreed well with our observed 1H-NMR data of 3 (Supplementary 
Fig. 10). An important structural difference between miyabeacin 3 and grandifloracin 5 is the oxidation level at 
C-8 and C-21 (COOH vs CH2OH) and hence the orientation of the ester linkage of the attached aromatic ring. 
The [4 + 2] cyclodimerisation of substituted cyclohexadienones is a well-known reaction in synthetic chemis-
try and, aside from grandifloracin, there are a number of other examples of this reaction occurring in the nat-
ural world24. A key feature of the reaction, whether proceeding in vivo or in vitro is the exquisite regio- and 
stereo-selectivity leading to entirely endo-stereochemistry in the product.
We tested miyabeacin against a range of cancer cell lines. Initial cell viability assays were carried out using the 
MYCN-amplified neuroblastoma cell line UKF-NB-3, established from a stage 4 neuroblastoma patient25 and 
the vincristine-resistant UKF-NB-3 sub-line UKF-NB-3rVCR10 (adapted to growth in the presence of vincristine 
10 ng/mL). At a concentration of 20 µg/mL of miyabeacin, the cell viability, relative to non-treated cells, after 
120 hours was 0% for UKF-NB-3 and 4.22 ± 2.89% for the vincristine resistant UKF-NB-3rVCR10 line. Initial 
IC50 values were obtained from an expanded range of cell lines including those in neuroblastoma (UKF-NB-3), 
breast (BT-474 and MCF-7), oesophageal (COLO-680N) and ovarian cancers (COLO-704 and EFO-21) (Table 3) 
and values ranged from 2.19–27.04 µg/mL. Three cell lines were selected and fully replicated IC50 data was 
obtained (Table 4). Mean values were calculated as 14.47 ± 5.69 µg/mL for the UKF-NB-3 neuroblastoma cell line, 
23.87 ± 19.93 µg/mL for the oesophageal cancer cell line COLO-680N and 34.45 ± 12.58 µg/mL for the COLO-
704 ovarian cancer cell line.
further structurally related natural products in S. miyabeana. An isomer of miyabeacin 3, peak 6 
(Fig. 2) with m/z 843.2349 (C40H43O20) was present in the LC-MS profile of S. miyabeana stem tissue at 24.27 min. 
MS-MS analysis of this m/z 843 ion gave no fragment ions. Isolation of 6 via collection of HPLC peaks from 
repeated injections afforded a pure sample. 1H-NMR spectroscopy showed a total of 17 signals which related to 
34 separate hydrogens in a highly symmetrical molecule (Table 1 and Supplementary Fig. 11). The presence of 
signals relating to benzyl and glucosyl moieties compared well with those observed in the 1H-NMR spectrum of 
3. Absence of the four olefin signals (δ5.91 to 6.59) previously observed in 3 was accompanied by a movement 
upfield of the four bridgehead hydrogens (δ3.43–3.63) to give a set of four signals at δ2.76, δ2.88, δ2.99 and δ3.12 
each integrating for 2 hydrogens. The 1H-NMR data suggested a further [2 + 2] intramolecular cyclization of the 
olefin units in 3 to give a “caged” structure which we have named miyabeacin B, 6. The cycloaddition of the dou-
ble bonds in 3 to yield the cyclobutyl ‘cage’ in 6 now confers a 2-fold axis of symmetry resulting in a significant 
simplification of the 1H-NMR spectrum for 6 relative to that of miyabeacin 3. This symmetry was also observed 
in the 13C data (Table 2) derived from HSQC and HMBC data (Supplementary Figs. 12, 13). [1H-1H] correlation 
spectroscopy confirmed the linkages around the tricyclic core of the molecule as indicated in Supplementary 
Table 2 and Fig. 14. The [2 + 2] annelation of 3 to give 6 mirrors that observed in laboratory photochemistry of a 
range of synthetic analogues of the [4 + 2] cyclodimerisation core structure24.
A third, structurally related novel compound, miyabeanol 7, appeared, in the LC-MS, particularly of leaf tis-
sue (Fig. 2), at 20.13 min. The MS spectrum contained three relevant ions at m/z 531.1551 (C26H27O12), 467.1159 
(C21H23O12) and 421.1120 (C20H21O10). A small ion at m/z 217.0507 (C12H9O4) was also present (Supplementary 
Fig. 15A). The 1H NMR spectrum of the HPLC purified compound (Table 1 and Supplementary Fig. 16) sug-
gested an analogous structure to the cyclodimer miyabeacin 3, although certain regions of the spectrum, includ-
ing those relating to the benzyl and glucosyl groups, were no longer duplicated suggesting that one of each of 
these units had been lost. 1H signals at δ6.63 and δ6.02 corresponded to those observed in 3 and related to the 
enone hydrogens, H-12 and H-13. Signals corresponding to the isolated olefin hydrogens at δ6.27 and δ5.94 were 
also present. These data and additional 1H-1H COSY correlations of these signals to 4 additional methine hydro-
gen atoms confirmed that the molecule retained the Diels-Alder “core” present in 3 (Supplementary Table 3 and 
S17). The NMR data were consistent with the MS data and suggested that compared to 3, compound 7 (MW 532, 
C26H28O12) was missing a salicin side chain and a carboxy group. The remaining peaks in the MS spectrum (m/z 
421.1120 and 467.1159), (Supplementary Fig. 15) were annotated as “salicortenone” 4 and its formate adduct 
and were believed to have arisen from a retro- Diels Alder fragmentation in the MS source. 13C NMR showed 26 
separate carbon signals including two ketone signals at δ213.3 and δ199.0 (Table 2). The position of side-chain loss 
and decarboxylation was confirmed via extensive analysis of COSY, HSQC and HMBC correlation spectroscopy 
(Supplementary Table 3 and Figs. 17–19). Key 1H-13C correlations were between H-10 and C-8, H-10 to C-14 and 
H-13 to C-9. This allowed placement of the carboxy-salicylglycoside moiety at C-9. However, no signals or corre-
lations were evident to H-20, suggesting that hydrogen-deuterium exchange, through an ene-diol canonical form, 
had occurred with the NMR solvent. However, use of 100% D2O as solvent (Supplementary Table 3), revealed the 
peak representing C-20 at 81.4 ppm and correlations from H-16, H-18 and H-10 to C-20 (δ81.4) were all present 
as well as those from H-15 and H-18 to the carbonyl at C-19.
A related minor compound 8 at 23.67 min in the LC-MS analysis (Fig. 2) displayed an [M-H]− ion at m/z 
529.1355 corresponding to a molecule with molecular formula C26H26O12, two mass units less than miyabeanol 
7. MS-MS of m/z 529 gave a series of daughter ions including some that were two mass units less than the corre-
sponding ions in the MS-MS of 7 (Supplementary Fig. 20). Additionally, an extra fragment ion at m/z 159.0458 
corresponded to a fragment with a formula of C10H7O2. 8 was isolated by fraction collection from HPLC and the 
1H NMR spectrum showed a downfield shift of the bridge olefin hydrogens (compared to 7) and also contained 
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just two methine signals which were also well downfield of those seen in 7 (Supplementary Table 4 and Fig. 21). 
13C NMR data, derived from HSQC and HMBC experiments (Supplementary Figs. 22, 23) indicated twelve aro-
matic carbons of which six were consistent with those observed for a salicyl glycoside (Supplementary Table 4). 
Position
2
(D2O:CD3OD)
3
(D2O:CD3OD)
6
(D2O:CD3OD)
7
(D2O:CD3OD)
7
(D2O)
1 157.7 158.1 158.1 158.0 157.8
2 117.9 118.0 117.9 117.7 117.3
3 133.3 133.5/133.4 133.9 133.7 133.2
4 125.7 125.7/125.8 125.9 125.7 125.3
5 133.0 133.7/133.6 134.3 133.7 133.2
6 126.8 126.9 126.4 126.6 126.6
7 66.7 67.3 67.1 67.2 67.0
8 173.5 173.6 174.0 173.7 173.6
9 81.0 82.2 80.6 82.5 82.4
10 128.9 40.3 43.1 40.6 40.4
11 136.7 43.5 41.0 43.9 43.7
12 28.7 152.5 37.7 152.8 152.7
13 38.5 131.0 48.1 130.8 130.6
14 199.2 198.6 210.6 199.0 199.1
15 — 45.2 43.1 45.7 45.5
16 — 135.6 41.0 136.0 135.6
17 — 132.8 37.7 132.2 132.2
18 — 54.3 48.1 54.6 54.5
19 — 210.0 210.6 213.3 213.4
20 — 80.0 80.6 missing 81.4
21 — 173.3 174.0 — —
22 — 66.7 67.1 — —
23 — 126.7 126.4 — —
24 — 133.7/133.6 134.3 — —
25 — 125.7/125.8 125.9 — —
26 — 133.5/133.4 133.9 — —
27 — 117.8 117.9 — —
28 — 157.8 158.1 — —
1′ 102.8 103.1/103.0 102.9 103.0 102.7
2′ 75.9 76.1 76.0 76.0 75.8
3′ 78.7 79.2 79.0 79.1 78.7
4′ 72.2 72.5/72.4 72.8 72.4 72.2
5′ 78.7 78.7/78.8 79.0 78.8 78.5
6′ 63.4 63.7 63.9 63.6 63.5
1″ — 103.1/103.0 102.9 — —
2″ — 76.1 76.0 — —
3″ — 79.2 79.0 — —
4″ — 72.5/72.4 72.8 — —
5″ — 78.7/78.8 79.0 — —
6″ — 63.7 63.9 — —
Table 2. 13C-NMR data for salicortin 2, miyabeacin 3, miyabeacin B 6 and miyabeanol 7. δin ppm.
Cancer Type Cell Line
Miyabeacin IC50 (μg/
mL)
Breast BT-474 27.04
Oesophageal COLO-680N 5.08
Ovarian COLO-704 20.18
Ovarian EFO-21 12.69
Breast MCF-7 2.19
Neuroblastoma UKF-NB-3 7.12
Table 3. IC50 assessment of miyabeacin 3 in six cancer cell lines.
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Of the remaining aromatic C-signals, two were methines bearing hydrogens that were ortho-coupled (J = 8 Hz) 
to each other only, whilst the other four were quaternary, two of which were observed at δ144.5 and δ147.3 indi-
cating hydroxyl substitution. The deduced structure, miyaquinol 8 (Fig. 1) was confirmed by HMBC correlations 
to be an ortho-substituted di-phenolic ring fused to a bicyclo-octene moiety bearing a ketone at C-10 and the 
carboxysalicyl glucoside and hydroxyl groups at C-9.
[4 + 2] dimers are not confined to Salix miyabeana, and accumulate over the growth cycle. 
Juvenile leaf and stem tissue from 26 field-grown Salix species were profiled for the dimeric salicinoids 
(Supplementary Table 5). Significant levels (>40 mg/g d.w.) of dimeric analogues were found in 3 accessions 
(NWC941, NWC885 and NWC837) of S. miyabeana Seemen, and also in 2 accessions (NWC577 and NWC592) 
of S. dasyclados Wimm. Lower levels were found in 2 additional S. dasyclados Wimm. accessions (Fig. 3). Whilst 
ratios between miyabeacin 3, miyabeacin B 6 and miyabeanol 7 varied, all compounds were found in leaf tissue. 
In stem tissue, only 3 and 6 were detected. Of lines that produced dimeric compounds, there was a strong cor-
relation in the concentrations of miyabeacin 3 and miyabeacin B 6 (r2 > 0.95, p < 0.001) in both leaf and stem 
samples suggesting a direct biosynthetic relationship. A slightly lower correlation (r2 = 0.86, p < 0.001) between 
the concentration of miyabeacin 3 and miyabeanol 7 in leaf tissue (Supplementary Fig. 24), was also observed. 
Comparison of uHPLC-MS peak areas of miyabeanol 7 and 8 indicated a high degree of correlation (r2 = 0.982, 
p < 0.001) and a ratio of approximately 9:1 with 7 being the major of the two products (Supplementary Fig. 25).
To investigate the onset of dimeric salicinoid production and determine the temporal relationship of the 
cyclodimerisation with the production of salicortin and salicin, S. dasyclados tissue was sampled from 3 to 60 
days after budburst (phenological stage 10)19 from an array of pot-grown clones generated from cuttings and 
grown in controlled environment under long days. Destructive sampling was carried out daily at the same time 
from 3–10 days (T3-T10) and subsequently at 12, 15, 30, 45 and 60 days after bud burst (Supplementary Fig. 26). 
Compounds 3, 6 and 7 were quantified from 1H-NMR data alongside levels of salicin 1 and salicortin 2, saligenin 
(salicyl alcohol) and catechol by integration of compound specific NMR signals. In leaves, miyabeacin 3 and 
miyabeacin B 6 were present in very young T3 shoots at levels of 36 µmoles/g d.w and 1.9 µmoles/g d.w respec-
tively (Fig. 4A). Levels of these compounds increased from T3 to T8 and then remained level until T15. Levels 
increased further at T30 and T45 until finally falling at T60. A correlation coefficient of r = 0.87 (p < 0.001) indi-
cated that production of these two dimeric entities were highly correlated (Fig. 4B) and confirmed the hypothesis 
that 6 is derived from 3 from a [2 + 2] cycloaddition reaction. Levels of salicortin 2 were in the same range (20–50 
µmoles/g d.w) but the trajectory was less correlated with 3 and 6 with a coefficient of r = 0.58. Levels of, miya-
beanol, 7 were inversely correlated (r = −0.63) with 3, being highest at T3 (69.9 µmoles/g d.w.) and falling to 10.4 
µmoles/g d.w. by T60. Salicin 1 levels were also highest at T3 (63.8 9 µmoles/g d.w.), decreased gradually across 
the time course and were highly correlated (r = 0.96) with miyabeanol, 7 concentrations. Similarly, catechol and 
saligenin levels also decreased from T30 to T60 and although observed at lower concentrations were highly cor-
related with salicin concentrations across the experiment (both having a correlation coefficient of r = 0.98 to sali-
cin). The data indicated a relationship of miyabeanol, 7 to salicin 1, saligenin and catechol which was in contrast 
to the increasing levels of miyabeacin, 3 and salicortin 2.
In stem tissue from the same plant samples the concentration profiles (Fig. 4C) of all metabolites mirrored that 
observed in leaf tissue with the exception of miyabeanol, 7 which could only be detected in the very juvenile stem 
tissue of young T3 and T4 shoots. It is possible that 7, is only produced in leaves and that at the very early time 
points T3 and T4, the stem and leaf are not yet fully differentiated.
the cyclodimerization process is heritable and substrate driven giving rise to “cross-over” 
Diels-Alder products. S. miyabeana and S. dasyclados have been used as breeding parents for the genera-
tion of willow lines with improved biomass traits. The commercial variety “Terra Nova”, a hybrid arising from S. 
miyabeana, S viminalis and S. triandra (Supplementary Table 6) was analysed by LC-MS (Supplementary Fig. 27) 
which confirmed the presence of cyclodimeric analogues 3, 6 and 7 in juvenile leaf tissue. In line with the parent, 
S. miyabeana, cyclodimers were also present in the stem tissue with the exception of 7. A more striking example 
of the heritability of the cyclodimer production was observed for the biomass variety “Endurance”, a hybrid of 
S. rehderiana and S. dasyclados (Supplementary Table 6), the former a species of willow that produces acetylated 
salicinoids. The LC-MS profile (Supplementary Fig. 28) again contained compounds 3, 6 and 7 but also contained 
related compounds all bearing at least one acetyl moiety. Compound 9 gave a peak at 27.21 min and had an 
[M-H]− ion at m/z 885.2456 corresponding to a neutral molecule with a molecular formula of C42H46O21. Smaller 
ions at m/z 421.1142 (C20H21O10) and 463.1244 (C22H23O11) were also present in the spectrum (Supplementary 
Fig. 29A). Isolation via HPLC peak collection and collection of 1H-NMR spectra indicated a 1:1 mixture of mon-
oacetylated miyabeacin isomers (9a and 9b), confirmed by the presence of two new 3 H singlets at δ2.143 and 
Cancer Type Cell Line
Miyabeacin IC50 Concentration (µg/mL) IC50 (μM)
expt 1 expt 2 expt 3 mean S.D. Mean ± S.D.
Oesophageal cancer COLO-680N 5.08 15.08 51.46 23.87 19.93 28.28 ± 23.61
Ovarian cancer COLO-704 20.18 32.38 50.79 34.45 12.58 40.18 ± 14.90
Neuroblastoma UKF-NB-3 7.12 20.97 15.33 14.47 5.69 17.15 ± 6.74
Table 4. Replicated IC50 determination of miyabeacin 3 in three cancer cell lines.
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δ2.137. Appearance of 2 double doublets (J = 8.0, 9.6) at δ5.00 and δ4.97 placed the acetyl moiety in the glucose 
groups at 2′ in one isomer and at 2′′ in the alternate compound (Supplementary Table 7). Substitution on the 
glucosyl ring now produced separated signals across the 1H spectrum for H-1′/1′′, H-3′/3′′, H-4′/4′′ and H-5′/5′′. 
Additionally, benzyl hydrogens (H2−7) showed an upfield shift due to acetylation at the 2′-position and now 
appeared at δ5.09/ 5.03 in 9a while corresponding H2−22 moved to δ5.10/ 5.03 in 9b when acetylation occurred 
at the 2′′-position. A full 1H and 13C spectral assignment (Supplementary Table 7) was achieved via the use of 
2D COSY, HSQC, HMBC and TOCSY experiments and comparison to 1H-NMR data from 3 and 7. Key COSY 
correlations between the 1′/1′′ and 2′/2′′ peaks confirmed the position of acetylation and further confirmation 
of the 2′/2′′-acetyl miyabeacin structures 9a and 9b was obtained via comparison of the MS-MS spectra with 
that of 3 (Supplementary Fig. 29B,C). Ions at m/z 123.0458 (C7H7O2), 201.0571 (C12H9O3), 245.0461 (C13H9O5), 
263.0576 (C13H11O6) and 289.0364 (C14H9O7) were identical to those obtained from MS-MS of m/z 843. A further 
ion appearing at m/z 599.1435 appears as well as the m/z 557.1324 ion observed from MS-MS of 3 and corre-
sponded to an acetylated derivative of this fragment with a formula of C29H27O14. The presence of both of these 
ions, arising from the loss of a single salicin fragment (Supplementary Fig. 1), is further evidence of a mixture of 
monoacetylated isomers.
A further compound 10 in Endurance gave an LC-MS peak at 29.05 min and had an [M-H]− ion at m/z 
927.2537 corresponding to a neutral molecule with molecular formula C44H48O22, suggestive of the diacetyl form 
of miyabeacin. MS-MS generated a spectrum that was identical to that obtained from 9a/9b (Supplementary 
Fig. 30) with the exception of the m/z 557 ion which was missing, indicating substitution on each salicin entity. 
1H-NMR data of 10 (Supplementary Table 8) showed two acetyl singlets at δ2.162 and δ2.156. Separate signals 
corresponding to 2′-H and 2′′-H appeared at δ4.98 and δ5.01 confirming acetyl substitution at the 2-position of 
the glucose moiety in both halves of the dimeric molecule.
From Endurance leaf tissue, 2′-acetyl miyabeanol 11 could also be identified from a peak at 23.08 min 
(Supplementary Fig. 28) with an [M-H]− ion at m/z 573.1603 corresponding to a molecular formula for the 
neutral molecule of C28H30O13 (Supplementary Fig. 31A). As previously observed with 7, ions arising from an 
in-source retro Diels-Alder reaction were also observed at m/z 463.1243 (C22H23O11) and 509.1295 (C23H25O13) 
and corresponded to the [M-H]− and formate adducts of 2′-O-acetyl “salicortenone”, 12. MS-MS fragmentation 
of 11 (Supplementary Fig. 31B) showed an initial loss of an acetyl salicin fragment and then a pattern of ions that 
followed identical fragmentation to that observed from MS-MS of 7. The presence of 13, 2′-acetylmiyaquinol, was 
indicated in the LC-MS analysis, where 2′-O-acetyl salicortin, 14 dominates (Supplementary Fig. 28), but levels 
were too low for isolation and NMR characterisation.
Further structural diversity was evident in the analysis of a S. miyabeana hybrid breeding line (RR10347) gen-
erated from a cross of RR05326 (Resolution × NWC609 S. rossica) with NWC941 (S. miyabeana Purpurescens). 
Analysis of RR10347 by LC-MS (Supplementary Fig. 32) indicated the presence of tremulacin 15 (C27H28O11), a 
2′-O-benzoylated derivative of salicortin which is well known in the Salicaceae16. A new peak also appeared at 
Figure 3. Concentration of miyabeacin, 3, miyabeacin B, 6 and miyabeanol, 7 in juvenile tissue of S. dasyclados 
and S. miyabeana accessions. (A) Leaf data; (B) Stem data.
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30.95 min with a mass of 947.2561 that corresponded to an [M-H]− ion from a neutral molecule of molecular 
formula C47H48O21. As in the case of the mass spectrum of 3, a smaller ion (m/z 421.1125) corresponded to 
that observed for “salicortenone” 4 (C20H21O10). An additional small ion (m/z 525.1465) was also evident with a 
suggested formula of C27H25O11. MS-MS of m/z 947.2561 yielded two strong ions at m/z 121 (C7H5O2) and m/z 
123 (C7H7O2), the former corresponding to a benzoate moiety and the latter to a salicyl moiety. The data were 
suggestive of 16a/16b, novel mono-benzoylated derivative of miyabeacin 3. The peak was isolated by repeated 
injection into an HPLC system and the structure characterised by 1H-NMR (Supplementary Fig. 33). This data, 
via comparison to the NMR spectrum of 3, confirmed the presence of a dimeric compound. Additional peaks at 
δ8.06, δ7.70 and δ7.54 were characteristic of a benzoate group but a doubling of most peaks indicated a 1:1 mix-
ture of isomers which could not be separated further. A set of multiplet peaks appearing at δ5.25 confirmed the 
benzoyl substitution at the 2′-position of the glucoside in the first isomer (16a) and the 2′′-position in the second 
isomer (16b). This was further confirmed in the 1H-1H -COSY spectrum (Supplementary Fig. 34).
Figure 4. Quantified metabolite concentrations from NWC577 S. dasyclados grown in controlled conditions 
across a 60-day timecourse. Data is coloured according to harvest time with labelling representing the number 
of days post bud burst. (A) leaf data; (B) Pearson correlation coefficients for metabolite pairs; (C) stem data.
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A further example, extending the range of substituted dimeric compounds was seen in the LC-MS analysis 
of a willow breeding line (RR10147) developed as part of a biomass improvement programme at Rothamsted 
Research. This hybrid line included S. dasyclados (NWC577) in both parents [RR07187 (NWC944 S. glaucophy-
loides × NWC577 S. dasyclados “77056”) × RR07188 (NWC944 S. glaucophyloides × NWC577 S. dasyclados 
“77056”)] as well as S. glaucophyloides (NWC944). In the Total Ion Chromatogram of the negative ion mode 
LC-MS data (Supplementary Fig. 35) salicortin 2, 2′-O-acetylsalicortin 14 and tremulacin 15 appeared as major 
peaks. Given that this cross has generated a hybrid capable of producing both acetylated and benzoylated sali-
cinoids alongside salicortin it followed that associated dimeric analogues would also be expected to be formed 
via a matrix of cross-over reactions involving the three corresponding dienones 2,12 and 17. This was indeed 
the case with miyabeacin 3 appearing at 25.03 min, 2′/2′′-O-acetylmiyabeacin 9a/9b appearing at 26.90 min 
and 2′/2′′-O-benzoylmiyabeacin 16a/16b appearing at 30.95 min. A further intriguing peak was observed at 
32.48 min which showed an ion at m/z 989.2617, corresponding to a formula of C49H49O22. Although there was 
insufficient for isolation, the MS was suggestive of the predicted miyabeacin analogue bearing both an acetyl and 
benzoyl substitution.
Discussion
The identification of miyabeacin 3 and its analogues in Salix spp. adds further examples to the group of natural 
products that are formed from intermolecular Diels-Alder, cyclodimerisation reactions of ortho-quinonoids24. 
These precedents include dimers of terpenoid and polyketide intermediates, but also the phenolic-derived ana-
logue, grandifloracin 5 which bears strong structural similarities to the aglycone of miyabeacin, although it is 
important to note that, relative to 5, the side-chain ester functions of 3 are inversely orientated, and also that in 
the case of miyabeacin the reaction involves highly polar glycosylated reactants. The obligate substrate for the for-
mation of miyabeacin by cyclodimerisation in willow is the substituted ortho-quinol, salicortenone 4 which has a 
dienone unit that behaves as both a diene and a dienophile, the latter reacting through the distal double bond of 
the dienone (C-10 and 11) as shown in Fig. 5. This reaction, for these types of orthoquinol reactants, is known to 
be exquisitely regio- and stereo-specific to give only endo- products with no known natural compounds resulting 
from either exo-processes or reaction at the alternate double bond of the dienophile (in this case C12 and 13, 
Fig. 5.)24,26. In this work we have also identified a further dimeric natural product – the ‘cage’ compound, miya-
beacin B 6 that arises from an additional [2 + 2] photo-annelation reaction of the [4 + 2] Diels Alder product. 
There are also precedents, in synthetic examples, for this conversion24 which again confirms the endo selectivity of 
the preceding [4 + 2] reaction as the double bonds in the corresponding exo products are not aligned for [2 + 2] 
cage formation. The natural [4 + 2] reaction occurs spontaneously at ambient temperature and, as yet, there has 
been no evidence provided, for any enyzme directly catalysing intermolecular Diels-Alder reactions24. However, 
we have now presented strong evidence from analysis of breeding parents and progeny that the ability to produce 
the cyclodimers is a heritable trait that is genetically encoded in S. miyabeana and S. dasyclados and their progeny. 
Furthermore, the observation of cross-over [4 + 2] cycloaddition reactions when Salix genotypes for example, 
S. rehderiana that produces 2′-acetylsalicortin 14 and S. rossica that produces 2′-benzoylsalicortin (tremulacin) 
15 are crossed, respectively, with S. dasyclados and S. miyabeana, provides further compelling evidence for the 
inheritance of the Diels-Alder capability. An exquisite example of the combinatorial nature of the reactions was 
observed in the complex hybrids that contain both 2′-acetyl and benzoyl substrates as well as the [4 + 2] capability 
from S. dasyclados, where all possibilities of cross-over dimerisations were observed. These results also indicate 
that the glucose and substituted glucose moieties in miyabeacin and its analogues must be already present in 
the dienone substrates, indicating that glycosylation, and 2′-acylation of that glucoside, are earlier steps in the 
salicinoid pathway.
Apart from the unlikely possibility of the direct involvement of a gene-encoded protein that binds 2 molecules of 
the monomer salicortenone 4 (and/or its acylated analogues) and facilitates the cyclodimerisation, the most likely 
explanation of the heritability of the production of miyabeacin and its relatives is that in S. miyabeana and S. dasy-
clados there is genetic control of the production or accumulation of the dienones such as 4. This novel trait/gene is 
not present or not functional in willow lines that only express the common pathway to salicortin and analogues such 
as tremulacin. The production of the cross-over [4 + 2] products bearing acyl groups when two analogous salicor-
tenones are co-biosynthesised supports the argument that the pool size of salicortenones is genetically controlled. 
Given that the spontaneous [4 + 2] dimerisation is under kinetic control, concentrations of precursor in planta are 
a major determinant. Many willow species make salicortin and given the structural similarity of salicortenone to 
salicortin it is likely that they are closely related biosynthetically. Two biosynthetic scenarios are possible as shown 
in Fig. 6. The first and more straightforward possibility is that salicortenone 4, and hence miyabeacin 3, are metab-
olites of salicortin 2, formed from an oxidative dehydrogenation process (e.g. via a P450 reaction) inheritable from 
S. miyabeana or S. dasyclados. In this scenario an extra gene, present in S. miyabeana or dasyclados, is carried into 
hybrid progeny where, depending on the species, a variety of salicortin derivatives are presented to the new enzyme 
for conversion to the dienone and hence the dimers. Endurance inherits the [4 + 2] process from S. dasyclados and 
the 2′-acetylation trait from S. rehderiana. The observation that mono-acetylmiyabeacins 9a and 9b are produced 
in a 1:1 ratio indicates that pools of “salicortenone” 4 and “acetylsalicortenone” 12 are both available for “cross-over” 
dimerization reactions, and that, in planta, the acetylation of the glucose moieties occurs before, rather than after, 
the Diels-Alder reaction. The dienones 4 and 12 could not be identified in the samples, and thus remain obligate but 
undetected biosynthetic intermediates. The biosynthetic precursor or catabolite relationship of salicortin 2 to the 
structurally close dienone 4 is also unclear, but relative levels of salicortin 2 and 2′-acetylsalicortin 14 in the hybrid 
may be expected to predict the ratios 3, 9(9a + 9b) and 10 produced in the cross-over reaction. Salicortin 2 and 
2′-acetylsalicortin 14 were quantified directly from 1H-NMR data of the plant extracts and occurred in a ratio of 6:1 
in stems and 1:2 in leaves. Visual inspection of LC-MS analysis of Endurance (Supplementary Fig. 28) shows that the 
population of cyclo-dimers containing 0,1 or 2 acetyl groups on the glucose moieties do reflect the relative levels of 
1 1Scientific RepoRtS |         (2020) 10:6477  | https://doi.org/10.1038/s41598-020-63349-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
salicortin 2 and 2′-acetylsalicortin 14 in the two tissues. However, the ratios of 3,  9 and 10 are not totally consistent 
with the notion of simultaneous formation and free mixing of pools of salicortenone 4 and 2′-acetylsalicortenone 
12, which would predict that more 10 than 3 would be produced in leaves where acetylsalicortin 14 predominates 
over salicortin 2. The observed ratios of cross-over dimers suggest that the affinity of the oxidative enzyme proposed 
in scenario 1 (Fig. 6.) may be slightly different for salicortin 2 and the acetyl analogue 14 (and thus also 15), which 
can explain why the observed ratio of 3, 9a + 9b and 10 differs from that expected by the relative concentrations of 
2 and 14, particularly in leaf tissue.
The alternate, but more complex, biosynthetic scenario 2 (Fig. 6), begins with oxidative dearomatisation27 
of salicin-7-salicylate to produce salicortenone 4 as a transient intermediate in the biosynthesis of salicortin 2. 
Here we suggest that a “normal” intimate coupling (channelling) between the enzyme(s) that produces 4 and a 
reductive enzyme, that potentially converts 4 to salicortin via a 1,4-reduction process, is impaired in S. miya-
beana and S. dasyclados, resulting in pooling and hence spontaneous dimerisation of a significant proportion of 
4. However, both S. miyabeana and S. dasyclados still produce salicortin 2, and thus the reduction process cannot 
be completely impaired. In this biosynthetic scenario it is this partial loss of reductive function is passed on to 
the hybrids, a situation that is genetically more complex, but against a background of polypoid genomes, may 
have more to do with titre of fully coupled and functional reductases. The time-course data (Fig. 4) suggests that 
salicortin and miyabeacin production in planta are linked, but this would be so in both scenarios 1 and 2 (Fig. 6).
The origins of miyabeanol 7 and the minor related miyaquinol 8 which occur only in leaves, and very young 
green shoots at T3 and T4 (Fig. 4) is also not completely clear. Chemically, 7 and 8 could arise, in the plant or on sam-
ple processing, from hydrolytic removal of a salicin 1 moiety from miyabeacin 3 with concomitant decarboxylation 
(for 7) or aromatisation via loss of HCOOH (for 8). We cannot rule out non-enzymic hydrolysis completely but the 
lack of 7 in mature stem tissue that accumulates 3 indicates that the hydrolysis is not artifactual due to processing, 
but would need to be specific to photosynthetic tissue, suggesting involvement of a leaf carboxyesterase. In vitro, 
miyabeacin 3 was found to be stable, in neutral aqueous solution for several months, but underwent hydrolysis in 
mild alkaline solution to give salicin, miyabeanol 7, miyaquinol 8 and catechol. Thus, another explanation for spatial 
differences in the occurrence of 7 in planta, could be a pH difference in the two tissues. The strong correlation of 
miyabeanol, salicin and catechol accumulation in the leaf time-course (Fig. 4) indicates that a significant portion of 
salicin production in S. miyabeana and S. dasyclados in this tissue occurs through the turnover of miyabeacin via 
miyabeanol. However, in mature stem tissue, where miyabeanol is absent, this route is perhaps less important, and 
the salicin may arise from the ‘normal’ route shared with other Salix genotypes. This ‘normal’ route to salicin is not 
clear but may involve direct synthesis from salicylaldehyde28 or via cleavage of esters such as salicin-7-benzoate and/
or downstream products such as salicortin17. The degree of relocation of molecules from leaf to stem is an unknown 
factor and it should also be noted that salicortin is also susceptible to hydrolysis in vitro, the major products being 
salicin and catechol29,30. Thus, in summary, a network of potential routes to salicin exists, which in S. miyabeana and 
S. dasyclados appears to be supplemented by a considerable contribution from miyabeacin catabolism.
The pharmaceutical activity of salicin 1 is well known, but the potential pharmacology of miyabeacin 3 is per-
haps much wider. Structurally, it contains two salicin groups that give it potential ‘double dose’ anti-inflammatory 
and anti-thrombolytic activities associated with salicin and aspirin. However, our results reporting the activity of 
miyabeacin 3 against a number of cancer cell lines including cell lines with acquired drug resistance, adds further 
evidence for the multi-faceted pharmacology of willow. Of particular note is the activity against neuroblastoma 
cell lines. Overall survival rates are below 50% and it represents the most frequent extracranial solid childhood 
tumour31. With resistance acquisition being a significant issue in neuroblastoma32, new drugs with novel modes 
of action are required and miyabeacin perhaps offers a new opportunity in this respect.
Methods
plant tissues. Field material. For the initial analyses, multiple juvenile shoots were harvested in May 2014 from 
the new growth of S. miyabeana Seemen “Shrubby” (plot 885 of the National Willow Collection (NWC), Rothamsted 
Research, UK) that had been coppiced at the end of the previous growing season. Plant tissue from 10 separate plants 
was combined to generate a homogeneous sample. Tissue was stored at −80 °C prior to lyophilisation. Leaves and stems 
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Figure 5. The formation of miyabeacin, 3 via cyclodimerization of salicortenone, 4.
1 2Scientific RepoRtS |         (2020) 10:6477  | https://doi.org/10.1038/s41598-020-63349-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
were separated prior to milling to a fine powder (Retsch Ultra Centrifugal Mill ZM200, Retsch, UK). Milled tissue was 
maintained at −80 °C until analysis. A voucher specimen has been retained and is available on request. Additional 
sampling for comparative miyabeacin assessment in other species took place from the same collection within 2 weeks. 
Tissues were harvested at the same time of day, and were harvested and processed using identical protocols
Generation of plant tissue for detailed timecourse. 15 cm cutting stems of S. dasyclados (NWC577), harvested 
from the National Willow Collection, Rothamsted Research, UK during dormancy (December 2014), were 
removed from cold storage (−4 °C), fully defrosted for 6 hours, then soaked overnight in tap water. 50 Cutting 
stems were planted at half-depth in individual pots (15 cm Ø, 15 cm tall, volume 1.55 L) consisting of a 50:50 v/v 
of perlite and Rothamsted Standard Compost Mix (75% Medium grade (L&P) peat, 12% Screened sterilised loam, 
3% Medium grade vermiculite, 10% Grit (5 mm screened, lime free) plus 3.5 kg Osmocote Exact 3/4 month per 
m3). Plants were grown under controlled environment conditions, set to achieve an average of 600 μmol·m−2·s−1 
measured at plant growth height (2.5 m from light source). Plants were grown under 14/10 hr day/nights at 
18 °C/10 °C and 60%/90% relative humidity. Plants were observed daily for signs of budburst and tagged (T0) 
when they achieved this (normally 7 to 10 days from planting). “Budburst” corresponded with the Weih defini-
tion of bud burst (stage 3)33 and stage 10 as suggested by Saka and Kuzovkina19 10 whereby “green tip elongates 
but leaves till remain in a tight cluster (>5 mm)”. Tissue from multiple shoots was cut with scissors and immedi-
ately snap-frozen in liquid nitrogen at the following number of days after budburst (T): 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 
30, 45 and 60. For T3-T5 stages tissue from 2 plants (multiple stems) were pooled for each biological replicate. For 
the remaining timepoints, a single plant’s shoots were harvested. Three biological replicates per timepoint were 
harvested. Tissue was kept at −80 °C prior to lyophilisation. Stem and leaf tissues were separated prior to milling 
to a fine powder using a pestle and mortar. Milled tissue was maintained at −80 °C until analysis.
Figure 6. Proposed biosynthetic scenarios leading to miyabeacin, 3 and downstream products.
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Metabolite extraction. For 1H-NMR and LC-MS metabolomics analysis freeze-dried plant tissues were 
extracted by established protocols34–36. Briefly, ground, freeze-dried tissue aliquots (15 mg) were extracted 
in H2O:MeOH (4:1)(1 mL) for LC-MS and D2O:CD3OD (4:1 containing 0.01% w/v d4−3-(trimethylsilyl)
propionic-2,2,3,3 acid)(1 mL) for 1H-NMR. Extractions were carried out at 50 °C for 10 min. After cooling and 
centrifugation, samples were heated to 90 °C for 2 min. Resultant supernatants were transferred to appropriate 
vials for LC-MS analysis or 5 mm NMR tubes for 1H-NMR profiling. For the isolation of pure compounds for 
structural characterisation, identical procedures were followed. Ratios of plant tissue to extraction solvent are 
provided in Supplementary Table 9.
nMR and Mass Spectroscopy. 1H-1D and 1H-1H & 1H-13C 2D-NMR spectra were acquired on a Bruker 
Avance 600 MHz NMR spectrometer (Bruker Biospin, Germany), operating at 600.05 MHz for 1H and 150.9 MHz 
for 13C NMR spectra, using a 5 mm selective inverse probe. Full details (typical scan numbers, parameter sets, 
pulses, spectral information) are provided in Supplementary Table 10. NMR data was processed using TOPSPIN 
v. 2.1 (Bruker Biospin, Germany), and ACD NMR Processor (ACD Labs, Toronto, Canada). Metabolite quantita-
tions were carried out using a known concentration of internal standard (d4−3-(trimethylsilyl)propionic-2,2,3,3 
acid) and characteristic chemical shift regions for each metabolite.
UHPLC–MS spectra were recorded with an Dionex UltiMate 3000 RS UHPLC system, equipped with a DAD-
3000 photodiode array detector, coupled to an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, 
Germany). Chromatographic separation was performed at 35 °C using a reversed-phase Hypersil GOLD™ col-
umn (1.9 μm, 30 × 2.1 mm i.d. Thermo Fisher Scientific, Germany). The solvent system consisted of water/0.1% 
formic acid (A) and acetonitrile/0.1% formic acid (B), both Optima™ grade (Thermo Fisher Scientific, Germany). 
Separation was carried out for 40 min under the following conditions: 0–5 min, 0% B; 5–27 min, 31.6% B; 
27–34 min, 45% B; 34–37.5 min, 75% B. The flow rate was 0.3 mL/min, and the injection volume was 10 μL. Mass 
spectra were collected in negative mode using an LTQ-Orbitrap Elite with a heated ESI source (Thermo Fisher 
Scientific, Germany). Full parameters used are provided in Supplementary Table 10. Data was collected and 
inspected using Xcalibur v. 2.2 (Thermo Fisher Scientific, Germany).
Compound isolation. Purification of target compounds was carried out using an HPLC system (Agilent 1100 or 
Dionex Ultimate 3000) equipped with a quaternary pump, diode array detector, column oven and autosampler. 
Peaks were separated using an Ascentis C-18 column (5 μm, 5 × 250 mm i.d., Supelco, UK) maintained at 25 °C. 
Peaks were detected using wavelengths of 254 nm and the peaks corresponding to target compounds were col-
lected, in automation, by time into glass tubes. Solvents were evaporated using a Speedvac concentrator (Genevac, 
Suffolk, UK). For the generation of bulk extracts, plant tissues were extracted in water:methanol (4:1) using an 
extraction temperature of 50 °C as described above. Specific details regarding starting tissue weights, extraction 
volumes, HPLC gradients and amounts of purified compounds generated are given in Supplementary Table 9.
Optical rotation. Optical rotation was measured in water on an Anton Paar MCP-100 polarimeter using a 
100 mm sample cell. The specific rotation of miyabeacin 3 was determined as [α]25D − 59.4 (c 0.155, H2O).
cell lines. The MYCN-amplified neuroblastoma cell line UKF-NB-3 was established from a stage 4 neuro-
blastoma patient25. The vincristine-resistant UKF-NB-3 sub-line UKF-NB-3rVCR10 (adapted to growth in the 
presence of vincristine 10 ng/mL) was established by previously described methods25 and derived from the 
Resistant Cancer Cell Line (RCCL) collection (https://research.kent.ac.uk/industrial-biotechnology-centre/
the-resistant-cancer-cell-line-rccl-collection/)37. The oesophageal cancer cell line COLO680N was obtained from 
ATCC (Manassas, VA, USA) and the ovarian cancer (COLO-704 and EFO-21) and breast cancer (BT-474 and 
MCF-7) cell lines from DSMZ (Braunschweig, Germany). All cell lines were propagated in Iscove’s modified 
Dulbecco’s medium (IMDM) supplemented with 10% FCS, 100 IU/ml penicillin and 100 mg/ml streptomycin 
at 37 °C. Cells were routinely tested for mycoplasma contamination and authenticated by short tandem repeat 
profiling.
cell viability assays. Cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)−2,5-diph
enyltetrazolium bromide (MTT) dye reduction assay after 120 h incubation as described previously38. Briefly, 
5000 cells (suspended in 100 µL IMDM supplemented with 10% FCS, 100 IU/ml penicillin and 100 mg/ml strep-
tomycin) were incubated in 96-well plates at 37 °C and 5% CO2 with the investigated extracts for 120 h. MTT 
solution (25 µL of a 2 µg/mL solution dissolved in PBS) was added for 4 h. This was followed by the addition of 
sodium dodecyl sulphate solution (100 µL of 20% 50:50 purified water/ DMF) adjusted to pH 4.7 for an additional 
4 h in order to lyse cells and dissolve formazan precipitates. Plates were read at 600 nm. The relative viability was 
determined as the relative reduction of the optical density relative to an untreated cell control (=100%). IC50 val-
ues were determined using CalcuSyn software (Biosoft, Cambridge, UK).
Received: 8 November 2019; Accepted: 27 March 2020;
Published: xx xx xxxx
References
 1. Stone, E. An account of the success of the bark of willow tree in the cure of agues. Philos. Trans. Roy. Soc. London 53, 195–200 (1763).
 2. Feistel, F., Paetz, C., Lorenz, S. & Schneider, B. The absolute configuration of salicortin, HCH-salicortin and tremulacin from Populus 
trichocarpa × deltoides Beaupré. Molecules 20, 5566–5573 (2015).
 3. Leroux, H. Discovery of salicine. J. Chim. Med. 6, 340–432 (1830).
 4. Vane, J. R. & Botting, R. M. The mechanism of action of aspirin. Thrombosis Res. 110, 255–258 (2003).
1 4Scientific RepoRtS |         (2020) 10:6477  | https://doi.org/10.1038/s41598-020-63349-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
 5. Higgs, G. A., Salmon, J. A., Henderson, B. & Vane, J. R. Pharmacokinetics of aspirin and salicylate in relation to inhibition of 
arachidonate cyclooxygenase and anti-inflammatory activity. Proc. Natl. Acad. Sci. USA 84, 1417–1420 (1987).
 6. Li, Y. et al. (−)-Salicin inhibits the LPS-induced inflammation in RAW264.7 cells and mouse models. Int. Immunopharmacology 26, 
286–294 (2015).
 7. Chan, N. C. & Weitz, J. I. Antithrombotic agents, New directions in antithrombotic therapy. Circulation Res. 124, 426–436 (2019).
 8. Kong, C. S. et al. Salicin, and extract from white willow bark, inhibits angiogenesis by blocking the ROS-ERK pathways. Phytotherapy 
Res. 28, 1246–51 (2014).
 9. Wolfle, U. et al. Salicin from willow bark can modulate neurite outgrowth in human neuroblastoma SH-SY5Y cells. Phytotherapy 
Res. 29, 1494–1500 (2015).
 10. Rothwell, P. M. et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised 
trials. Lancet 376, 1741–50 (2010).
 11. Rothwell, P. M. et al. Effect of daily asprin on long-term risk of death due to cancer: analysis of individual patient data from 
randomised trials. Lancet 377, 31–41 (2011).
 12. Bonaterra, G. A., Kelber, O., Weiser, D., Metz, J. & Kinscherf, R. In vitro anti-proliferative effects of the willow bark extract STW 
33-I. Arzneimittel-Forschung 60, 330–5 (2010).
 13. Schmid, B., Kotter, I. & Heide, L. Pharmacokinetics of salicin after oral administation of a standardised willow bark extract. Eur. J. 
Clin. Pharmacol. 27, 387–391 (2001).
 14. Vlachojannis, J. E., Cameron, M. & Chrubasik, S. A systematic review on the effectiveness of willow bark for musculoskeletal pain. 
Phytotherapy Res. 23, 897–900 (2009).
 15. Dragos, D. et al. Phytomedicine in joint disorders. Nutrients 9, 70–88 (2017).
 16. Boeckler, G. A., Gershenzon, J. & Unsicker, S. B. Phenolic glycosides of the Salicaceae and their role as anti-herbivore defences. 
Phytochemistry 72, 1497–1509 (2011).
 17. Babst, B. A., Harding, S. A. & Tsai, C.-J. Biosynthesis of phenolic glycosides from phenypropanoid and benzenoid precursors in 
Populus. J. Chem. Ecol. 36, 286–297 (2010).
 18. Noleto-Dias, C., Ward, J. L., Bellisai, A., Lomax, C. & Beale, M. H. Salicin-7-sulfate: A new salicinoid from willow and implications 
for herbal medicine. Fitoterapia 127, 166–172 (2018).
 19. Saska, M. M. & Kuzovkina, Y. A. Phenological stages of willow (Salix). Annals Appl. Biol. 156, 431–437 (2010).
 20. Liao, Y.-H. et al. Three cyclohexene oxides from Uvaria grandiflora. Phytochemistry 45, 729–732 (1997).
 21. Awale, S. et al. Anti-austerity agents from Uvaria dac and their preferential cytotoxic activity against human pancreatic cancer lines 
in a nutrient-deprived condition. J. Nat. Prod. 75, 1177–1183 (2012).
 22. Palframan, M. J., Kociok-Kohn, G. & Lewis, S. E. Total synthesis of (+) grandifloracin by iron complexation of a microbial arene 
oxidation product. Org. Lett. 14, 3150–3153 (2011).
 23. Bergner, M., Duquette, D. C., Chio, L. & Stolz, B. M. Exceedingly efficient synthesis of (±) grandifloracin and acylated analogues. 
Org. Lett. 17, 3008–3010 (2015).
 24. Gangepain, J. et al. Regio- and stereo-selectivities in Diels-Alder cyclodimerizations of orthoquinonoid cyclohexa-2,4-dienones. 
Tetrahedron 63, 6493–6505 (2007).
 25. Kotchetkov, R. et al. Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on 
P-gp expression. Int J Oncol. 27, 1029–37 (2005).
 26. Deffieux, D., Fabre, I., Titz, A., Leger, J.-M. & Quideau, S. Electrochemical synthesis of dimerizing and nondimerizing orthoquinone 
monoketals. J. Org. Chem. 69, 8731–8738 (2004).
 27. Baker Dockery, S. A., Lukowski, A. L., Becker, M. R. & Narayan, A. R. H. Biocatalytic site- and enantioselective oxidative 
dearomatisation of phenols. Nature Chemistry 10, 119–125 (2018).
 28. Zenk, M. H. Pathways of salicyl alcohol and salicin formation in Salix purpurea L. Phytochemistry 6, 245–252 (1967).
 29. Lindroth, R. L. & Pajutee, M. S. Chemical analysis of phenolic glycosides: art, facts and artifacts. Oecologia 74, 144–148 (1987).
 30. Ruuhola, T., Julunen-Tiitto, R. & Vainiotalo, P. In vitro degradation of willow salicylates. J. Chem. Ecol. 29, 1083–1097 (2003).
 31. Maris, J. M. Recent advances in neuroblastoma. N. Engl. J. Med. 362, 2202–2211 (2010).
 32. Chen, L. & Tweddle, D. A. p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance. Front. Oncol. 
2, 173 (2012).
 33. Weih, M. Genetic and environmental variation in spring and autumn phenology of biomass willows (Salix spp.): effects on shoot 
growth and nitrogen economy. Tree physiology. 29, 1479–1490 (2009).
 34. Ward, J. L., Harris, C., Lewis, J. & Beale, M. H. Assessment of 1H-NMR spectroscopy and multivariate analysis as a technique for 
metabolite fingerprinting of Arabidopsis thaliana. Phytochemistry 62, 949–957 (2003).
 35. Corol, D. I., Harflett, C., Beale, M. H. & Ward, J. L. An efficient high throughput metabotyping platform for screening biomass 
willows. Metabolites 4, 946–976 (2014).
 36. Noleto-Dias, C. et al Phenylalkanoid glycosides (Non-Salicinoids) from wood chips of Salix triandra x dasyclados hybrid willow. 
Molecules 24 1152.
 37. Michaelis, M., Wass, M. & Cinatl, J. The resistant cancer cell line (RCCL) collection. Cancer Drug Resistance 2(3), 447–456 (2019).
 38. Michaelis, M. et al. Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen. Sci Rep. 5, 
8202 (2015).
Acknowledgements
Rothamsted Research receives grant-aided support from the Biotechnology and Biological Sciences Research 
Council (BBSRC) of the UK. We thank Gianluca Ruvo for NMR data collection. Yanqi Wu was funded via a 
grant awarded by the Engineering and Physical Sciences Research Council [EP/K014676/1]. The project also 
received funding from a grant awarded by the High Value Chemicals from Plants Network, a BBSRC Network 
in Industrial Biotechnology and Bioenergy (NIBB)”. Grant Ref: BB/L013665/1. The work described in this study 
was also supported by successive Institute Strategic Programme grants: Cropping Carbon [BBS/E/C/00005199] 
and Tailoring Plant Metabolism [BB/E/C/000I0410], funded by the BBSRC. Willow breeding through the BEGIN 
project was funded by the Department for Environment, Food and Rural Affairs [NF0424] and built upon the 
work of the European Willow Breeding Partnership (EWBP).
Author contributions
J.L.W. and M.H.B. were responsible for the conception and design of the study; Y.W., C.H., D.C., C.L and 
J.L.W. conducted the experiments; J.L.W. and Y.W. undertook the spectroscopic data analysis and structure 
determination; M.M. and M.N.W. conducted and supervised the bioactivity assessment. H.O. undertook the 
bioactivity assessment. M.M. and J.C. provided essential materials; W.J.M. maintained willow germplasm and 
assisted in collection. J.L.W. and M.H.B prepared the manuscript.
1 5Scientific RepoRtS |         (2020) 10:6477  | https://doi.org/10.1038/s41598-020-63349-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
competing interests
A number of the authors (Y.W., J.L.W., M.H.B. and M.M.) are inventors on a patent filed by Rothamsted 
Research concerning the anti-cancer activity of miyabeacin (GB1901272.3, Novel compounds & their use in 
therapy).
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-63349-1.
Correspondence and requests for materials should be addressed to J.L.W. or M.H.B.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
